Cannabidiol potentiates pharmacological effects of Δ9-tetrahydrocannabinol via CB1 receptor-dependent mechanism

Brain Research

Volumn 1188, Issue 1, 2008, Pages 157-164

  Hayakawa, Kazuhide ^a   Mishima, Kenichi ^a   Hazekawa, Mai ^a   Sano, Kazunori ^a   Irie, Keiichi ^a   Orito, Kensuke ^b   Egawa, Takashi ^a   Kitamura, Yoshihisa ^a   Uchida, Naoki ^a   Nishimura, Ryoji ^a   Egashira, Nobuaki ^a   Iwasaki, Katsunori ^a   Fujiwara, Michihiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b AZABU UNIVERSITY   (Japan)

Author keywords

9 tetrahydrocannabinol; Cannabidiol; CB1 receptor; Central nervous system; Marijuana

Indexed keywords

CANNABIDIOL; CANNABINOID 1 RECEPTOR; DRONABINOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CATALEPSY; CHEMICAL INTERACTION; CONTROLLED STUDY; CORPUS STRIATUM; HIPPOCAMPUS; HYPOTHALAMUS; HYPOTHERMIA; IMMOBILIZATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM TEMPERATURE; SPATIAL MEMORY; TASK PERFORMANCE;

ANIMALS; BODY TEMPERATURE; BRAIN; CANNABIDIOL; CATALEPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HYPOTHERMIA; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; MOTOR ACTIVITY; PSYCHOTROPIC DRUGS; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL;

CANNABIS; CANNABIS SATIVA; MUS;

EID: 37349071370     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.09.090     Document Type: Article

References (47)

1. Ashton C.H., Moore P.B., Gallagher P., and Young A.H. Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. J. Psychopharmacol. 19 (2005) 293-300
2. Baker D., Pryce G., Davies W.L., and Hiley C.R. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol. Sci. 27 (2006) 1-4
3. Begg M., Pacher P., Batkai S., Osei-Hyiaman D., Offertaler L., Mo F.M., Liu J., and Kunos G. Evidence for novel cannabinoid receptors. Pharmacol. Ther. 106 (2005) 133-145
4. Bisogno T., Hanus L., Petrocellis L., Tchilibon S., Ponde D.E., Brandi I., Moriello A.S., Davis J.B., Mechoulam R., and Marzo V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134 (2001) 825-852
5. 9-tetrahydrocannabinol. Res. Commun. Chem. Pathol. Pharmacol. 7 (1974) 663-670
6. Bornheim L.M., Kim K.Y., Li J., Perotti B.Y., and Benet L.Z. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab. Dispos. 23 (1995) 825-831
7. Carrier E.J., Auchampach J.A., and Hillard C.J. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc. Natl. Acad. Sci. USA. 103 (2006) 7895-7900
8. Egashira N., Matsuda T., Koushi E., Mishima K., Iwasaki K., Shoyama Y., and Fujiwara M. Involvement of 5-hydroxytryptamine1A receptors in Delta9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice. Eur. J. Pharmacol. 550 (2006) 117-122
9. 9-THC actions by cannabinol and cannabidiol in the rat. Psychopharmacologia 38 (1974) 329-338
10. Fujiwara M. Characteristics of abnormal behavior induced by delta 9-tetraydrocannabinol in rats. Nippon Yakurigaku Zasshi 117 (2001) 35-41
11. Fujiwara M., and Egashira M. New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application. J. Pharmacol. Sci. 96 (2004) 362-366
12. Groenewegen H.J., Vermeulen-Van, der, Zee E., te, Kortschot A., and Witter M.P. Organization of the projections from the subiculum to the ventral striatum in the rat. A study using anterograde transport of phaseolus vulgaris leucoagglutinin. Neuroscience 23 (1987) 103-120
13. 9-THC) and cannabidiol (CBD) in aggression, muscle control and body temperature experiments in mice. Psychopharmacologia 41 (1975) 169-174
14. Heyser C.J., Hampson R.E., and Deadwyler S.A. Effects of delta-9tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J. Pharmacol. Exp. Ther. 264 (1993) 294-307
15. Heydorn A., Sondergaard B.P., Ersbøll B., Halst B., Nielsen F.C., Haft C.R., Whistler J., and Schwartz T.W. A library of 7TM receptor C-terminal tails. Interactions with the proposed post-endocytic sorting proteins ERM-binding phosphoprotein 50 (EBP50), N-ethylmaleimide-sensitive factor (NSF), sorting nexin 1 (SNX1), and G protein-coupled receptor-associated sorting protein (GASP). J. Biol. Chem. 279 (2004) 54291-54303
16. Inui K., Egashira N., Mishima K., Yano A., Matsumoto Y., Hasebe N., Abe K., Hayakawa K., Ikeda T., Iwasaki K., and Fujiwara M. The serotonin1A receptor agonist 8-OHDPAT reverses delta9-tetrahydrocannabinol-induced impairment of spatial memory and reduction of acetylcholine release in the dorsal hippocampus in rats. Neurotox. Res. 6 (2004) 153-158
17. Jaeger W., Benet L.Z., and Bornheim L.M. Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica 26 (1996) 275-284
18. Jones G., and Pertwee R.G. A metabolic interaction in vivo between cannabidiol and 1-tetrahydrocannabinol. Br. J. Pharmacol. 45 (1972) 375-377
19. 9-tetrahydrocannabinol. Psychopharmacologia 33 (1973) 53-70
20. Karniol I.G., Shirakawa I., Kasinaki N., and Carlini E.A. Cannabidiol interferes with the effects of delta9-tetrahydrocannabinol in man. Eur. J. Pharmacol. 28 (1974) 172-177
21. Kathmann M., Flau K., Redmer A., Trankle C., and Schlicker E. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn. Schmiedebergs. Arch. Pharmacol. 372 (2006) 354-361
22. Leterrier C., Bonnard D., Carrel D., Rossier J., and Lenkei Z. Constitutive endocytic cycle of the CB1 cannabinoid receptor. J. Biol. Chem. 279 (2004) 36013-36021
23. Lisman J.E., and Grace A.A. The hippocampal-VTA loop: controlling the entry of information into long-term memory. Neuron 46 (2005) 703-713
24. MacDonald N.A., Henstridge C.M., Connolly C.N., and Irving A.J. Generation and functional characterization of fluorescent, N-terminally tagged CB1 receptor chimeras for live-cell imaging. Mol. Cell Neurosci. 35 (2007) 237-248
25. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdan R.K., Johonson M.R., Melvin L.S., Mecholam R., and Ward S.J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 40 (1991) 471-478
26. Mecholam R., Parker L.A., and Gallily R. Cannabidiol: an overview of some pharmacological aspects. J. Clin. Pharmacol. 42 (2002) 11S-19S
27. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., Costa B.R., and Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. 87 (1990) 1932-1936
28. 9-tetrahydrocannabinol in rats. Jpn. J. Pharmacol. 87 (2001) 297-308
29. Murillo-Rodriguez E., Millan-Aldaco D., Palomero-Rivero M., Mechoulam R., and Drucker-Colin R. Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS. Lett. 580 (2006) 4337-4345
30. Nagai H., Egashira N., Sano K., Ogata A., Mizuki A., Mishima K., Iwasaki K., Shoyama Y., Nishimura R., and Fujiwara M. Antipsychotics improve Delta9-tetrahydrocannabinol0induced impairment of the prepulse inhibition of the startle reflex in mice. Pharmacol. Biochem. Behav. 84 (2006) 330-336
31. Nie J., and Lewis D.L. Structural domains of the CB1 cannabinoid receptor that contribute to constitutive activity and G-protein sequestration. J. Neurosci. 21 (2001) 8758-8764
32. O'Donnell P., and Grace A.A. Synaptic interactions among excitatory afferents to nucleus accumbens neurons: Hippocampal gating of prefrontal cortical input. J. Neurosci. 15 (1995) 3622-3639
33. Olton D.S., and Samuelson R.J. Remembrance of places past: spatial memory in rats. J. Exp. Psychol., Anim. Behav. Process 2 (1976) 97-116
34. Rakhshan F., Day T.A., Blakely R.D., and Barker E.L. Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J. Pharmacol. Exp. Ther. 292 (2000) 960-967
35. Russo E., and Guy G.W. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med. Hypotheses 66 (2006) 234-246
36. Russo E.B., Burnett A., Hall B., and Parker K.K. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem. Res. 30 (2005) 1037-1043
37. Tanda G., Munzar P., and Goldberg S.R. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat. Neurosci. 3 (2000) 1073-1074
38. Varvel S.A., Wiley J.L., Yang R., Bridgen D.T., Long K., Lichtman A.H., and Martin B.R. Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology 186 (2006) 226-234
39. Vialou V., Balasse L., Dumas S., Giros B., and Gautron S. Neurochemical characterization of pathways expressing plasma membrane monoamine transporter in the rat brain. Neuroscience 144 (2007) 616-622
40. Walaas I., and Fonnum F. Biochemical evidence for glutamate as a transmitter in hippocampal efferents to the basal forebrain and hypothalamus in rat brain. Neuroscience 5 (1980) 1691-1698
41. Watanabe K., Arai M., Narimatsu S., Yamamoto I., and Yoshimura H. Self-catalyzed inactivation of cytochrome P-450 during microsomal metabolism of cannabidiol. Biochem. Pharmacol. 36 (1987) 3371-3377
42. Watanabe K., Kayano Y., Matsunaga T., Yamamoto I., and Yoshimura H. Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Biol. Pharm. Bull. 19 (1996) 1109-1111
43. Welburn P.J., Starmer G.A., Chesher G.B., and Jackson D.M. Effect of cannabinoids on the abdominal constriction response in mice: within cannabinoid interactions. Psychopharmacologia 46 (1976) 83-85
44. Wiley J.L., and Martin B.R. Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chem. Phys. Lipids 121 (2002) 57-63
45. Wise R.A. Neuroscience of addiction. Neuron 21 (1998) 467-476
46. Yim C.Y., and Mogenson G.J. Low doses of nucleus accumbens dopamine modulate amygdala suppression of spontaneous activity. Brain Res. 477 (1989) 202-210
47. 9-THC in normal subjects. Psychopharmacology (Berl) 76 (1982) 245-250